

Pre Q

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Levitsky et al.

Application No. Unassigned

Filed: November 16, 2001

Art Unit: Unassigned

Examiner: Unassigned

For: A UNIVERSAL IMMUNOMODULATORY
CYTOKINE-EXPRESSING BYSTANDER
CELL LINE AND RELATED
COMPOSITIONS AND METHODS OF
MANUFACTURE AND USE

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to the examination of the above-identified patent application, please enter the following amendments and consider the following remarks.

AMENDMENTS

IN THE SPECIFICATION:

The paragraph beginning at page 20, line 12, has been amended to read:

Q' As shown in Fig. 1, subclones of GM-CSF-producing K562 cells produced in excess of 1,000 ng/10⁶ cells/24 hrs. The use of such subclones enables the use of as few as one bystander cell per 10 autologous tumor cells with a clear margin of safety above the GM-CSF threshold of 36 ng GM-CSF/10⁶ cells/24 hrs, by targeting 100 ng/10⁶ cells/24 hrs.

IN THE CLAIMS:

Please cancel claims 15, 16, 29-39, 48 and 49.

Please amend the indicated claims to read as follows:

- Q2 1. A universal bystander cell line, which:
(i) is a human cell line,

0992443-11601
"PCT" CH2660